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Abstract 
INHIBITION OF MARGINATION AND DIAPEDESIS OF NEUTROPHILS BY 
PROTEIN SYNTHESIS BLOCKADE 
By Phyllis V. Acquah, BS, M.Phil 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science in Biochemistry at Virginia Commonwealth University. 
Virginia Commonwealth University, 2006 
Major Director: Dr. Robert Diegelmann, Ph.D 
Professor, Department of Biochemistry 
Acute Respiratory Distress Syndrome (ARDS), an age-old clinical problem facing the 
Emergency Department and Intensive Care Units of all health systems, is a common 
debilitating lung condition consequent upon severe systemic inflammation. Although 
several studies have gone into understanding the epidemiology and pathogenesis of the 
disease thus making way for new advances in treatment strategies, there seems to be no 
known study tailored to its prevention. Neutrophil extravasation within the tissues during 
inflammation is the hallmark of this syndrome. Our study, sought to block excessive 
neutrophil infiltration by inhibiting the biosynthesis of some essential proteins necessary 
for the process. In .this initial study, neutrophil transmigration was successfully reduced 
by 66% using protein synthesis inhibitors, a combination of puromycin and anisomycin. 
Our strategy, if fine-tuned, could form the basis of a new clinical strategy for the 
prevention of ARDS. 
Funded by: VCURES (Dr. Kevin R. Ward) 
Literature Review 
Introduction 
Neutrophils, or polymorphonuclear leukocytes (PMN), are indispensable in 
mammalian host defense during infection. They are part of the innate immune system, 
which is very much involved in the first few hours of injury or infection before .the 
adaptive immune system is activated. Although, the role of neutrophils is vital at the site 
of inflammation, their activities have also been implicated in the parthenogenesis of 
certain clinical conditions following their activation. An exaggerated neutrophil 
activation due to extensive tissue injury or shock causes systemic inflammatory response 
syndrome, which could lead to acute respiratory distress syndrome (ARDS) and 
subsequently, multiple organ failure (MOF) [I]. 
Acute Respiratory Distress Syndrome (ARDS) 
Acute respiratory distress syndrome (ARDS) is a debilitating inflammatory 
condition resulting from an acute, severe lung injury to most or all of both lungs. Patients 
with ARDS experience severe shortness of breath and often require mechanical 
ventilation due to respiratory failure. The condition is characterized by fluid-filled 
alveoli and decreased lung compliance following extensive lung inflammation and small 
vessel injury[2]. ARDS is a syndrome not a specific disease, with predisposing factors 
like sepsis, trauma, and/or pneumonia. In ARDS, there is diffuse alveolar damage, 
resulting from structural changes in the alveolocapillary unit. Injury to the 
alveolocapillary membrane inevitably disrupts the endothelial barrier leading to the 
development of noncardiogenic pulmonary edema through increased vascular 
permeability. As the air spaces fill with fluid, the gas-exchange and mechanical 
properties of the lung deteriorate[3]. 
ARDS was first described in 1967 by Ashbaugh and collaborators, who observed 
12 of 272 patients treated for respiratory failure, with the following unique features: 
cyanosis refractory to oxygen therapy, decreased lung compliance, and diffused infiltrates 
evident on chest radiograph that distinguished them from the others[4]. Initially, the 
condition was called adult respiratory distress syndrome but, in 1994, the American- 
European Consensus Committee on ARDS standardized the definition and renamed it 
"acute" rather than "adult" because it occurs in all ages[5]. 
The incidence rate of ARDS ranges from 1.5 to 71 per 100,000 persons and 
affects about 150,000 each year in the United States. This syndrome is a major cause of 
morbidity, death, and cost in intensive care units [6]. The mortality rate of ARDS has 
been estimated to be approximately 30 - 40 %,[7-101 with the deaths usually resulting 
from multi-system organ failure rather than lung failure alone[2]. The majority of ARDS 
patients who survive will make a full recovery; however, some will have lasting damage 
to their lungs. According Herridge and colleagues, survivors of ARDS may experience 
persistent functional disability even one year after discharge from the intensive care unit, 
mostly muscle wasting and weakness [I I]. Thus, ARDS affects not only the patient, but 
also family members by way of stress and cost. 
Patients who experience severe trauma or sepsis are at increased risk for the 
development of ARDS with an onset between 24 and 72 hours of injury. In an event of 
severe infection or trauma, neutrophils are activated and recruited to the site of injury. 
This is the body's initial immune response to foreign invasion. The immune response to 
trauma is often exaggerated and the activated neutrophils extravasate not only to the site 
of infection, but also to distant tissues. Thus, the immunoactivation, though of benefit at 
the site of injury, has the potential to cause cell-mediated damage at remote organs[l]. In 
normal circulation, neutrophils constitute about 60% of leukocytes, but in ARDS total 
percentage can be as high as 90% in the lungs alone. The principal players involved in 
ARDS are cytokines, neutrophils, endothelium, and reactive oxygen species [12]. 
Neutrophils 
Neutrophils are described as the "first line of defense" in the body's immune 
response because ,they are the first to be recruited to the sites of inflammation. At the site, 
their targets include bacteria, fungi, protozoa, viruses, viral- infected cells and tumor 
cells. Like macrophages, neutrophils are called professional phagocytes, because, they 
hunt and kill microbes by ingesting them. 
Description 
Neutrophils are small cells, measuring about 9-1 0 pm in diameter. They are the 
most abundant leukocyte (50% -60% of leukocytes) in blood, with mean concentration of 
4.4 x 1 o6 cells/ml. They differ from the other leukocytes by their characteristic segmented 
nuclei (2-5 lobes), however, 5% of them have "banded" nuclei. They also possess a large 
quantity of storage granules in the cytoplasm and glycogen in the cytosol. Functionally, 
the granules are divided into three types: azurophils (primary granules), specific 
(secondary) granules, and storage granules. 
Maturation and Fate of Neutrophils 
Neutrophils begin their two-week lifespan in the bone marrow, where they 
differentiate and proliferate. During this period, they undergo six morphological stages: 
myeloblast, promyeloblast, myelocyte, metamyelocyte, non-segmented (band) neutrophil, 
and segmented neutrophil. The segmented neutrophil is terminally differentiated and a 
fully functionally active cell. It is during the mitotic phase of the promyelocytic stage that 
neutrophils begin to produce azurophil granules, which contain enzymes such as 
myeloperoxidase and elastase. In addition, in human neutrophils, the azurophil granules 
contain cationic antibacterial protein 37 and azurocidin[l3, 141. The azurophil granules 
are called "primary granules" because they are the first to appear in differentiation. 
Specific granules appear next and are called "secondary granules". They are made in the 
"myelocyte" stage (near the end of the mitotic stage). Specific granules contain lactoferin 
and lysozme and they outnumber (1 20- 140 granules/cell) the azurophils (60-70 
granules/cell). 
Most of the neutrophils formed in the bone marrow never enter circulation; 
instead they are phagocytosed by bone macrophages. The few that are released from the 
bone marrow after maturation circulate in the bloodstream in a non-activated state, 
having a half-life of approximately 4-1 0 hours. Thereafter, the neutrophils enter the tissue 
pools, where they survive for another 1 to 2 days after which time they are cleared from 
circulation. Their viability is however greatly shortened in patients suffering from 
infections or acute inflammatory diseases, in whom tissue requirement for newly 
recruited neutrophils becomes overwhelmingly higher. 
Activities of Neutrophils 
Under normal physiologic conditions, non- activated neutrophils stay in constant 
circulation and occasionally probe the vascular endothelium for the opportunity to 
transmigrate. Leukocyte recruitment has an important endothelial cell-dependent 
component and involves a series of adhesion steps: margination, rolling, activation and 
firm adhesion, and diapedesis (Fig. 1). 
Picture adapted from: www.bio.davidson.edu/coursedim~nunology 
Figure 1: Neutrophil recruitment. A schematic showing the four steps in 
neutrophil migration into the tissues and the chemokines that aide the process. 
During inflammation, the endothelial cells become activated by cytokines such as 
interleukin-1 (IL-I), Tumor Necrosis Factor a (TNF-a), and bacterial products such as 
endotoxin (lipopolysaccharide, LPS) leading to the up-regulation of cell surface adhesion 
molecules[l5-171 (Fig. 2). 
Neutrophil - Enduthelial Cell tigands 
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Figure 2: Neutrophil and endothelial cell Ligands. The different types of adhesion 
molecules expressed during neutrophil recruitment. [Picture adapted from Journal of Pharmacol Rev. 
52(3): 349-374 (2000)I 
The first group of adhesion molecules expressed is the selectins, specifically, E, L 
and P- selectins. They are vital to our body's immune response by recruiting and 
directing leukocytes and lymphocytes to sites of infection. In an event of an infection or 
injury, macrophages release TNF-a which stimulates the endothelial cells lining blood 
vessels to express P-selectin first, then, E-selectin (Janeway et al. 2005). P- selectins are 
pre-formed in vesicles called Weibel-Palade bodies near the cell surface of endothelial 
cells (Janeway, et a1 2005). The activation of TNF-a or LPS receptors on endothelial 
cells causes these vesicles to fuse with cell membrane, resulting in P-selectin expression 
within minutes of cytokine recognition. The story, however, is different for E- selectins, 
which have to be transcribed, translated and transported to the cell surface to be 
expressed. Thus, it takes about two hours after endothelial cell activation for E-selectins 
to be expressed, with peak expression between 6- 1 2 hours after cytokine recognition [ 181. 
L -selectin, on the other hand, is constitutively expressed on the surface of neutrophils. 
With endothelial cell activation, the neutrophils flowing in the center stream of the blood 
vessel begin to move towards the periphery, where they tether to the endothelial cells via 
the selectins. This initial attachment is called margination, and is a very important first 
step in the inflammatory cascade resulting in neutrophil rolling on the vessel wall. 
Rolling is mediated by low-affinity interactions between the selectins family 
(E/L/P-selectins) and sialyl LewisX glycans (sLewX ) [19-2 11. Both E and P -selectins are 
known to interact with sLewX glycans, which are constitutively expressed on the surface 
of neutrophils, but the actual role of L-selectin in rolling is yet to be fully elucidated. In 
trying to understand the roles of the three selectins in leukocyte rolling, Collins et a1[22] 
studied double-null selectin (E/P) and triple-null selectin (E/L/P) mice in infections. They 
noted that while the E/P-mutant mice developed both skin and pulmonary infections, the 
triple (E/L/P-selectins)- mutants did not. They therefore concluded that L-selectin 
deficiency alters the inflammatory response in E/P mutants. In another study, King and 
colleagues [23] also showed that the L-selectin receptors on neutrophils become clustered 
into a cap during rolling fostering a lower velocity movement than in cells with uniformly 
distributed L-selectin. 
The slow rate acquired by neutrophils is integral in the transition tofirm adhesion 
step by a second group of molecules called integrins. Prior to firm adhesion, chemokines 
such as interleukin- 8 (IL-8) and platelet activation function (PAF) stimulate neutrophils 
to upregulate Pz-integrins, which are Lymphocyte -associated Function Antigen-1, LFA- 
1, (CD 1 1 a/CD18), Macrophage antigen- 1, Mac- 1 (CD 1 1 bICD 1 8), and p 1 501 95 
(CD 1 lcICD18) as well as the vascular endothelium to express inter-cellular adhesion 
molecules (ICAM- 1 and 2), which belong to the immunoglobulin superfamily. On 
neutrophils, the distribution of LFA-1 is greater than the rest and has a higher affinity for 
ICAM-1 (CD54), but less affinity for ICAM-2[17, 24-26]. The binding of P2-integrins to 
the ICAMs arrests the rolling motion of neutrophils and ensures a firm adhesion, a 
phenomenon vital to leukocyte transmigration. According to one report [27] following 
IL-8 exposure, neutrophils shed their L-selectins to allow firm adhesion to take place. 
Firm adhesion of neutrophils to activated endothelium is an important step 
preceding diapedesis (transmigration) and also enables neutrophils to probe the vascular 
endothelium for an intercellular barrier. Platelet-Endothelial Cell Adhesion Molecule-1 
(PECAM- 1 or CD3 I), another immunoglobulin superfamily localized at the intercellular 
borders of endothelial cells mediates the process. PECAM-1 acts as glue that holds the 
adjoining cells together. Recent reports [28,29] indicate that leukocyte-derived 
azurocidin induces alteration of vascular permeability to permit diapedesis. The first 
assertion that azurocidin might play a role in endothelial permeability regulation was 
made by Ostergaard and Flodgaard [30] when they observed that fibroblast and 
endothelial monolayers treated with purified azurocidin exhibited reversible disruption of 
barrier function by cell contraction and the formation of large gaps between cells. 
However, for transmigration to proceed, the firmly adhered neutrophil must first flatten 
before squeezing between the adjoining cells to enter the tissues. In the tissues, 
chemotactic factors like complement protein (C5a), PAF, leukotriene B4 (LTB4), 
bacterial peptides, f-Met-Leu-Phe (MLP), or IL-8 [3 11 guide the transmigrated 
neutrophil to the site of inflammation for degranulation or phagocytosis to occur. 
Neutrophil's Armory 
Neutrophils have an incredible potent antimicrobial arsenal both within their 
granules and by their ability to produce reactive oxygen species. This array of weaponry 
is grouped as oxidative and non-oxidative "weapons" and they include oxidants, 
proteinases, and cationic peptides. 
Oxidative Microbicidal Mechanisms 
Free Radical Production 
There are two forms of free radicals produced by neutrophils (and other cells): 
reactive oxygen species and reactive nitrogen intermediates. The reactive oxygen 
intermediates are produced by the phagocyte NADPH oxidase, and are microbicidal [32]. 
Upon activation, neutrophils and mononuclear phagocytes increase their oxygen 
consumption, a process called respiratory burst. During this respiratory burst, the 
NADPH oxidase, an electron transport chain, reduces oxygen to superoxide anion or its 
protonated form, perhydroxyl radical, according to the equation below to form hydrogen 
peroxide. 
o ~ + c + H + + H O ~ * + * O - ~  +H+  
0 0 - 2  + 0 0 - 2  + 2 ~ +  -  0 2  + H202  
The hydrogen peroxide so formed interacts with myeloperoxidase to produce 
hypochlorous acid, which is antibacterial and cytotoxic. The hydroxyl radical (*OH) can 
be formed in several ways, but the decomposition of H202 catalyzed by Fe2+(Fenton 
reaction) is the most important. 
Fenton Reaction: 
Fe2+ + H202 -+ Fe3+ + OH. + OH- 
Reactive nitrogen intermediates (RNI) are the second group of free radicals 
formed by neutrophils. They originate from an oxidative pathway in which an unstable 
nitric oxide (NO*) is derived from the guanido nitrogen in the conversion of L-arginine to 
L- citrulline catalyzed by NO* synthase. It appears the antimicrobial activity is ROI 
dependent in normal neutrophils, but RNI may play a role in cells with deficiences in 
NADPH oxidaseIMP0 pathways. Nitric oxide may also contribute to the microbicidal 
activity of neutrophils by reacting with ROI to form secondary cytotoxic species such as 
peroxynitrite. 
Myeloperoxidase (MPO) the most abundant protein in neutrophils is a green 
lysosomal enzyme localized in the azurophil granules [33]. It catalyzes the reaction of 
hydrogen peroxide and chloride to hypochlorous acid [33-361, which is a potent 
antibactericidal [37]. This enzyme is considered a very important component of the 
neutrophil's antimicrobial armory. 
MPO plays a central role in infection and inflammation [36] and neutrophils 
require it to kill a variety of microorganisms [34]. It is released in phagocytosis during 
neutrophils' attack. Myeloperoxidase has also been implicated in promoting tissue 
damage in numerous inflammatory diseases including rheumatoid arthritis[38] , ARDS 
[39], multiple sclerosis [35], cystic fibrosis[40], and neonatal lung injury [41]. Recent 
reports further indicate that MPO triggers arterosclerosis by oxidizing low-density 
lipoproteins[42] and is implicated in acute myeloid leukemia[43], and lung cancer [44]. 
Non- Oxidative Microbicidal Mechanisms 
This category includes many components found in the granules, which are 
described as follows: 
Defensins are small, cysteine-rich cationic polypeptides, which exhibit powerful 
antimicrobicidal activities against a broad spectrum of microorganisms [45]. Their 
toxicity may involve the disruption of cell membrane of target cell leading to an increase 
in permeability and leakage of small molecules[46]. A Recent study has also linked 
defensins with tissue damage[47]. 
Bacterial Permeability- Increasing (BPI) protein is a 59 kDal cationic protein 
localized in azurophil granules of neutrophils. It does not require enzymatic activity to 
function and belongs to a class of proteins, which transport or bind cholesterol esters and 
lypopolisaccharides [48,49]. It exerts its antimicrobial activity by permeabilizing 
bacterial membrane [50]. 
Elastase, Cathepsin G, Proteinase 3, and Azurocidin are serine proteases 
(described as Neutral Serine Protease, NSP, family). They are highly cationic 
glycoprotein and are potent antiba.ctericidal[5 1-53]. Both elastase and cathepsin G appear 
to kill bacteria by two distinct mechanisms - enzyme-dependent and an enzyme - 
independent manner[54]. Elastase has also been known to specifically digest bacteria by 
degrading the outer membrane proteins, OmpA[55]. Azurocidin, however, has been 
found to be synergistic with elastase in killing bacteria [54]. Of these proteases, 
Proteinase 3 is the only one whose mechanism of killing still remains unclear. However, 
studies have also shown that these proteases when released can cause irreparable damage 
to tissues [56, 571. Proteinase 3 is the only other NPS that has been implicated in the 
immunopathogenesis of emphysema. 
Lnctoferrin, which localizes in the specific granules, is an iron-binding 
glycoprotein belonging to the transferrin family. Lactoferrin sequesters free iron with 
high affinity thereby preventing the growth of ingested microorganisms that survive the 
killing process and increase pernieability to lysozyme[58]. This is one more strategy of 
neutrophil's host defense mechanism. Another report also suggests Lactoferrin's 
bactericidal activities, which are independent of iron binding [59]. 
Matrix Metalloproteinases (MMPs) are a family of enzymes that is responsible 
for degradation of extracellular matrix components. Of these, MMP-8, a neutrophil 
collagenase, is of special interest to this research. By its remodeling action, MMP-8 
facilitates leukocyte trafficking through endothelial barriers and solid organs. MMP-8 
like other metalloproteinases is stored in the specific granules and is rapidly liberated in 
response to inflammatory mediators[60]. 
Each of these antimicrobial agents of neutrophil has, besides its microbicidal 
function, the capability also to damage the surrounding tissues. Many of previous studies 
have centered on the treatment of ARDS consequent upon neutrophil's damaging 
activity. However, this study seeks to use protein synthesis inhibitors as a strategy to 
prevent transmigration of neutrophils by inhibiting margination and/or diapedesis. This is 
an in vitro study, which uses Puromycin and Anisomycin combined to inhibit protein 
biosynthesis. 
Protein Synthesis Inhibitors 
Puromycin is an aminonucleoside antibiotic produced by Streptomyces alboniger. 
It inhibits protein biosynthesis by incorporating itself into a growing polypeptide chain at 
the A site and causes its premature termination. Because Puromycin resembles the 
aminoacyl terminus of an aminoacyl-tRNA (Fig. 3), it's amino group joins the carbonyl 
group of the growing polypeptide chain to form an adduct, which dissociates from the 
ribosome and becomes stable due to the amide group rather than an ester linkage (Berg et 
al, 2002). 
Diagram adapted from Figure 29.34. Biochemistry O 2002 by W. H. Freeman and Company 
Figure 3: An illustration of the structural similarity between puromycin and the 
aminoacyl terminus of an aminoacyl-tRNA that makes it possible to incorporate itself 
into the growing polypeptide. 
Anisomycin is an antibiotic isolated from Streptomyces griseolus with a structure 
established as 2-p-methoxyphenylmethyl-3-acetoxy-4-hydropyrrolidine (Fig. 4). It is 
known to inhibit protein synthesis by binding to 80s ribosomal subunits and blocking 
peptide bond elongation causing polysome stabilization[61]. Its action is described as 
potent, structurally specific, and reversibly inhibits protein biosynthesis in certain yeast 
and mammalian cells. In his study on the Mode of Action of Anisomycin, Grollman[62], 
reported a partial inhibition of DNA synthesis in Hela cells at anisomycin concentration 
which also produced 95% inhibition of protein synthesis. He also noted that the onset was 
rapid and reversible. Another effect of anisomycin on cells classified as stress, has been 
reported to strongly activate p38 and c J u n  N-terminal kinase (JNK) MAPK pathway[63] 
(Fig. 5). However, studies show that activation of MAPK pathway, which occurs at sub- 
trailslational inhibitory concentration, is dissociable from the translational arrest-related 
components[64,65]. 
Figure 4: The structure of Anisomycin 
Adapted from: http://kinase,uhnes.utoronto.cdmedidsignallingmap.html 
Figure 5: MAP Kinase signaling. A schematic showing stress-activated c-Jun and p38 
pathways. 
The Hypothesis 
Protein synthesis inhibitors can be used as a novel strategy to inhibit neutrophil 
transmigration and could form a basis for a therapy to prevent ARDS. 
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Figure 6: Mechanism of Protein Synthesis Inhibitors. An illustration of some protein 
synthesis inhibitors including anisomycin and puromycin [Picture adapted from an unknown 
location o f  the Internet] 
Materials and Methods 
Cell Culture 
The cell line, Human Microvascular Endothelial Cells (HMEC-l), used was a gift 
from the Center for Disease Control and Prevention (CID-R053413-OO)[Atlanta, GA]. 
The cells were initially cultured in MDCB 131 medium [Gibco, Grand Island, NY] 
supplemented with 20% Fetal Bovine Serum (Gibco, Grand Island, NY), 1% Antibiotic- 
Antimycotic (Penicillin, Streptomycin, and Amphotericin B) [Gibco: Grand Island, NY], 
1% L-Glutamine (Gibco: Grand Island, NY), 40ng/ml rh Epidermal Growth Factor 
(Invitrogen: Carlsbad, CA), and lugtml Hydrocortisone (Sigma: St. Louis, MO). Later 
on, culture media with reduced serum were used and were prepared from 1% or 2% Fetal 
Bovine Serum, 1% Insulin-Transferri-n-Selenium (see Appendix 2 for formulations) 
[Gibco, Grand Island, NY] 1% Antibiotic-Antimycotic (Penicillin, Streptomycin, and 
Amphotericin B), and 1 % L-Glutamine. 
Setting up an in vitro model 
A test model, which mimics the in vivo system of endothelium of the blood vessel and 
the tissue milieu, was adapted (Fig. 7). The model consisted of a 6.5 diameter transwell 
insert (Costar: Coming, NY) with polycarbonate membrane pore size of 3pm placed in a 
24-multiwell plate (Cellstar #662160) with medium. The transwell inserts were first 
coated with 6.6ug/ml of fibronectin (Fisher Scientific: Newark, DE) and allowed to 
incubate at room temperature under the laminar hood for one hour. After the incubation 
period, excess fibronectin liquid was discarded and the coated inserts were washed one 
time in sterile 1X Dubelco's PBS (Gibco: Grand Island, NY). 100p1 of growth medium 
containing 20,000 human microvascular endothelial cells (HMEC- 1.) were seeded onto 
the fibronectin coated inserts. Then 500p.1 of growth medium was placed in the well and 
the seeded transwell insert was placed in it. The cells were allowed to grow to confluence 
for up to 7 days at 37' C and 5% COz and fresh growth medium was replaced every other 
day. The monolayer formed represented the lining of the blood vessel. 
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Figure 7: An in vitro model of the blood vessel- tissue system in vivo. The upper 
compartment depicts the blood vessel with a monolayer of endothelial cells and the lower 
compartment represents the surrounding tissue into which the neutrophil migrate.[ 
Diagram adapted from the internet. Location: unknown] 
Determining the Integrity of HMEC-1 Monolayer 
Each day starting from the third day of growth, the integrity of monolayer was tested 
using the Bradford Protein assay. The inserts were removed from the incubator and 
washed twice in DPBS to remove traces of serum from the monolayer. 1 OOp 1 of 1 Opglml 
of BSA (Bio-Rad: Hercules, CA) in MCDB 13 1 was placed in the transwell inserts and 
500yl of basic MCDB 13 1 in the lower chamber. A control was included in each day's 
experiment. The control consisted of a transwell insert without a monolayer and was 
placed in a well containing 500~1  of medium; 100~1  of lOpg/ml BSA was then placed in 
the upper chamber. Triplicates of each set up were done and were incubated at 37OC and 
5% C02  for 45 minutes. After the incubation, the bottoms of the inserts were rinsed with 
the contents of the lower chamber and 200pl of the contents was transferred into a 
labeled 1.5 ml microcentrifuge tubes. 200pl of 1X Bradford Dye Reagent (Bio-Rad: 
Hercules CA) was added, vortexed, and incubated for 5 minutes at room temperature. 
100p1 of the suspension was transferred to a 96- well microplate and read at 595nm on a 
microplate reader. Standards were prepared according to the manufacturer's instruction 
[Bio-Rad: Hercules, CAI with a linear range of 1.25 -10pg/ml of BSA. The standard 
curve developed was used to determine the amount of albumin that had gone through the 
monolayer. By measuring each day's total protein leakage up to 7 days, it was possible to 
determine when the monolayer was ready for future transmigration experiments. 
Testing Lypopolyssachrides' Reaction with Myeloperoxidase ELISA Assay 
Standard myeloperoxidase solutions ranging from Ong/ml - 100ng/ml were 
prepared according to the manufacturer's protocol (Calbiochem, La Jolla, CA) [Appendix 
51. Later on, three concentrations of MPO, Ong/ml, 5ng/ml and 100ng/ml, were prepared 
in buffer (MCDB 131) with or without lnglml of lypopolysacchride, LPS (Sigma: St. 
Louis, MO). A blank, made up solely of the buffer was included. Both the standard 
solutions and the samples were tested with the ELISA assay [Appendix 51. MPO activity 
was measured at 450nm on a microplate reader. The standard curve was developed and 
used to calculate the amount of MPO activity seen with both the buffer and LPS. 
Investigating LPS Direct Effect on Neutrophils 
Approximately 500,000 purified PMNs (obtained from healthy volunteers) were 
added to lng/ml LPS in a 1.5 ml microcentrifuge tubes and incubated for 0, 15 and 30 
minutes at 37OC and 5% COz. At the end of the incubation, the PMN suspensions were 
vortexed and 1OOul transferred into a required number of strips of a 96-well polystyrene 
plate coated with antibody for MPO ELISA assessment. The presence of 
myeloperixidase was measured at 450nm using a microplate reader. 
Investigating LPS's and PSI'S Individual and Combined Effect on PMNs 
To determine if PSI could prevent neutrophil degranulation with LPS activation, 
500,000 neutrophils were placed in four separate 1.5 ml microcentrifuge tubes and either 
LPS (lng/ml), PSI (0.5uM puromycin and 0.12uM anisomycin), both, or nothing 
(control) was added. The neutrophils that received both reagents were first pre-treated 
with PSI for one hour followed by LPS for an additional hour. All samples were 
incubated at 37OC and 5% COz. Immediately after incubation, the suspensions were 
centrifuged at 18,000 x g at 4OC for 15 minutes to pellet the PMNs. After centrifugation, 
4 5 0 ~ 1  of the supernatant was discarded and 5 0 0 ~ 1  of cytobuster extraction protein 
(Novagen: Canada) was added and incubated on ice for another 15 minutes to lyse the 
PMNs. Following PMN lysis, MPO ELISA assay was performed to assess the amount of 
myeloperoxidase released. 
Determining Cell Viability With LPS or PSI Exposure 
Cell viability was tested after LPS and PSI separate exposures. Viable cell 
numbers were measured using 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium 
bromide (MTT)[Sigma: St. Louis, MO] assay. Approximately 50,000 HMEC-1 were 
cultured to confluence for 3days in a 96-well plate. The medium was aspirated and the 
cells were washed two times with 1X DPBS to remove all traces of serum. A dose 
response on cell viability was tested with LPS. To do this, lOOpl of different LPS 
concentrations, Ong/ml, 0.25ng/ml, O.Sng/rnl and lng/ml, were added to designate wells 
with cells and incubated for four hours. While cultures were incubating, MTT working 
solution was prepared by adding 3ml of MCDB 131 medium to a vial of MTT 
lyophilized reagent. After LPS treatment, the cultures were removed and lop1 of the 
MTT reconstituted solution was added to all wells and re-incubated for 2 hours. A purple 
precipitate (formazan) resulted from a reaction between mitochondria and MTT reagent. 
lOOpl of MTT Solubilization solution was added to dissolve the precipitate. Dissolution 
of crystals was expedited by carefully triturating the mixture with a micropipette. Two 
absorbance readings at 570nm and 690nm were taken. The latter reading at 690nm, 
which is the background absorbance, was deducted from the absorbance at 570nm to 
obtain a measure of cell viability. 
In the case of PSI, a time-course of HMEC-1 exposure to a single dose of PSI 
(0.5pM Puromycin + 0.12pM Anisomycin) was tested. The cells were exposed to PSI for 
different time periods at one hour intervals up to five hours and then analyzed by MTT 
assay for viability or cytotocity. 
Determination of TNFa's Optimal Concentration for PMN Transmigration 
In subsequent experiments, it became necessary to replace LPS with TNFa as a stimulant 
for PMN transmigration. And to determine the appropriate concentration for the assay, 
various TNFa concentrations, were tested on PMN transmigration. HMEC-1 monolayer 
preparations were exposed to TNFa concentrations of 2ng/ml, Sng/ml, and lOng/ml for 4 
hours. The length of time (4 hours) for TNFa to exert maximal effect was selected 
according to the method by Chen et. a1[66] . 
Meanwhile, PMNs were isolated from whole blood of healthy volunteers by 
density gradient separation (Appendix 3) using polymorphprep solution (Polymorphprep: 
Oslo, Norway). The purified PMNs were re-suspended in MCDB medium and the 
density was determined using a Coulter cell counter [Coulter Electronics Ltd., Luton, 
England]. The purified PMNs were kept on ice until needed. At the end of the monolayer 
treatment period, all inserts were washed two times in DPBS and placed in a 24-well 
plate containing 6 0 0 ~ 1  of O.lng/ml of interleukin - 8( Sigma: St. Louis, MO). 1 0 0 ~ 1  of
lo6 PMNs was also placed in all inserts. The sets were incubated at 37OC and 5% COz 
for 90 minutes. After that, cultures were removed from the incubator and the bottoms of 
the inserts were rinsed with the lower chamber contents to ensure no transmigrated PMN 
was sticking to the bottom. 4 7 5 ~ 1  of the lower chamber contents from each well was 
transferred into labeled micro-centrifuge tubes to which 2 5 ~ 1  of 20X Sample Buffer 
(Calbiochem, La Jolla, CA) was added and vortexed to ensure careful mixing. Following 
this, the MPO ELISA assay [Appendix 51 was performed to quantify transmigrated 
PMNs by measuring the presence of myeloperoxidase. The results obtained were 
recorded. 
Transmigration of PMNs after TNF-a and PSI treatment of Monolayer 
Triplicates of four categories of inserts with intact HMEC-1 monolayers were 
prepared. The experiment was designed and grouped as follows: Negative Control (#I), 
TNF-a-treated only (#2), PSI -treated only (#3), and PSI pre-treatment plus TNF-a co- 
treatment (#4). The Protein Synthesis Inhibitors (PSI) used was a combination of 0.5pM 
Puromycin (Sigma # P8833, St. Louis, MO) and 0.12pM Anisomycin (Sigma #A9789, 
St. Louis, MO). The combined concentration is also referred to in this study as 0.5X. This 
dosage of PSI was selected based on preliminary in vitro studies done in the lab by 
Quincy Tran on the reversibility effects of different concentrations of PSI on HMEC-1 
viability [Appendix 61. From his experiments, 0.5X PSI was the optimum dose that 
showed an inhibitory effect as well as a 95% cell recovery (in 48 hours). 
To begin the experiment, all sets were washed two times in 1X DPBS by carefully 
submerging to remove traces of serum. The experimental wells, #4, were first pre-treated 
with 0.5X PSI for one hour by placing lOOpl of PSI in the upper chamber and 500p1 in 
the lower chamber. Then TNFa (10ngIml) was added during the second hour for a total 
treatment time of 5 hours. Other monolayers were treated as appropriate. 
After the incubation, the treated monolayers were washed two times in 1X DPBS 
and the inserts were placed in wells containing 600p1 of O.lng/ml IL-8. 100p1 of lo6 
PMN suspensions was placed in all inserts and incubated for 90minutes at 37OC and 5% 
C02. After incubation, the bottoms of the transwell inserts were rinsed with the lower 
chamber contents and set aside. The contents of the lower chamber were carefully mixed 
and 475p1 was transferred into 1.5 ml microcentrifuge tubes to which 25 pl of 20X 
Sample buffer was added and vortexed for 30 seconds. 100pl of the suspension was 
transferred to 96-wells (Calbiochem: La Jolla, CA) for MPO ELISA analysis of 
myeloperoxidase (Appendix 5). The presence of myeloperoxidase was measured at 
450nm on a microplate reader and the results were analyzed. 
FA CS Analysis 
Measuring E-selectin 
Approximately 1 o6 HMEC-I cells were cultured in 75cm2 tissue culture flasks for 
4 days to confluence. Cells were exposed to various treatments as follows: Negative 
Control (no treatment), TNF-a treatment only, PSI treatment only, and PSI-TNF-a co- 
treatment. PSI treatment was for a total incubation time of Shours and TNF- a treatment, 
where applicable, was for a total time of 4hours. After treatment, cells were washed one 
time with DPBS and harvested by scraping with cell lifters (Costar: Corning, NY). When 
the cells had detached from the bottom of the flasks, the suspension was transferred into a 
15ml Falcon tube and triturated with pipette to loosen any clumped cells. The cell 
suspensions were centrifuged at 250 x g for 5 minutes to pellet and then washed one time 
in PSB+ 0.05% Tween (PBST). The washing was followed by a blocking step for which 
the cell pellet was incubated for 15 minutes with 1 % FBS in PBS to reduce non-specific 
binding. 
Later on, the cells were stained with monoclonal anti-human CD62E, FITC 
conjugate (Sigma: F0674, St. Louis, MO) for E-selectin analysis. In addition to that, a 
negative control for staining was set up to ensure a successful blocking step. For that 
purpose, approximately 200,000 cells treated with TNFu were stained with mouse IgG1, 
K- FITC conjugate isotype control (Sigma, # F6397). All cells were then washed in PBS 
+ 0.05% Tween 20(PBST) and re-suspended in medium for immediate flow cytometer 
analysis. Cells (control, treated and/or antibody incorporated) were analyzed using 
fluorescence-activated cytometer (Beckman Coulter Excel). Cells were gated using 
forward light scatter by side scatter absorbance. The analysis produced was based on 
10,000 events within the gated region. The percentages of cells with or wi.thout E-selectin 
were displayed on both dot-plots and histograms for analysis. 
Measuring Apoptosis after HMEC-1 Exposure to TNFa and LPS 
Cells were exposed to the various treatment conditions: no treatment, TNFa 
(1 Onglml), PSI, and PSI-TNFa. After treatment, the cells were immediately harvested 
with 3ml of Trypsin-EDTA for 2-5 minutes at 37°C. Cell harvesting with Trypsin-EDTA 
for this study was preferred to scraping since the latter appeared to permeabilize cells 
leading to increased cell death in HMEC-1. When cells had lifted off the flask, 5ml of 
growth medium was added to neutralize trypsin's enzymatic reaction. The cell 
suspension was centrifuged at 250 x g for 5 minutes to isolate the cells. The cell -pellets 
were washed twice in ice cold DPBS. Meanwhile, 1X annexin- binding buffer and 
100ug/ml Propidium Iodide (PI) working solutions were prepared from stock solutions 
provided in Vybrant Apoptosis Assay Kit (Molecular Probes: Eugene, Oregon) according 
to the manufacturer's protocol. After the last washing, the cells were re-suspended in 1X 
annexin-binding buffer and cell density was determined with the aide of a Coulter Cell 
Counter. For annexin positive control analysis, 5ul of Alexa Fluor 488(Molecular Probes: 
Eugene, Oregon) was added to every 100,000 cells in solution. Similarly, for PI positive 
control analysis, 1 p1 of 100ug/n1l propidium iodide was added per 100,000 cells. For 
each category of cells (control and treated) a combination of annexin and PI was added to 
determine total apoptosis induced. Staining was accomplished by incubating the 
cells with the stains in the dark for 15 minutes after which 4 0 0 ~ 1  of annexin-binding 
buffer was added to every 1 0 0 ~ 1  of 100,000- cell suspension. The stained cells were 
maintained on ice and immediately analyzed by flow cytometry as before. 
Analysis of the Effect of Lack of Serum on HMEC-1 
The effect of three types of growth media: 20% FBS, Serum - free, and Insulin- 
Tranferrin-Selenium-A (ITS) media, on HMEC-1 cell- proliferation was investigated. 
The serum-free medium was made from 1% L-Glutamine [Gibco: Grand Island, NY], 1% 
Antibiotic-Antimycotic (Penicillin, Streptomycin, and Amphotericin B) [Gibco: Grand 
Island, NY]. The ITS medium was also prepared from 1 %( IOOX) Insulin-Transferrin- 
Selenium-A (Gibco: Grand Island, NY) 1 %( 200mM), L-Glutamine (Gibco Grand 
Island, NY), 1 %( 100X) Antibiotic-Antimycotic (Gibco: Grand Island, NY) and MCDB 
131. First, 100,000 cells were seeded in 6-well plates and were grouped as control and 
experimental. A triplicate of each category was set up. The control set was cultured in 
20% FBS medium, and the experimental category had either serum-free or ITS medium. 
Growth pattern was monitored every 24 hours up to 5 days. After 4 days of growth when 
visual observation indicated severely impaired cell growths, 0.2% serum was added to 
cells receiving ITS only to see if serum would produce any change in growth pattern. All 
changes observed within 24 hours thereon were noted and carefully documented. 
The statistical method used in analyzing the data was student t-test with a 5% 
level of significance. 
Results 
Determining HMEC Monolayer Readiness 
The experiments begun by estimating if a well-formed monolayer was intact for 
subsequent transmigration experiments. Approximately, 20,000 HMEC- 1 cells were 
seeded in transwell inserts and one extra well with no insert for monitoring cell growth. 
The cultures were allowed to grow to confluence for seven days. Each day following the 
day of seeding, cell growth was visually monitored in the well with no insert to determine 
when a monolayer may have formed. It was observed that, on the aver&ge, from the third 
day of growth cells formed a cobblestone pattern indicative of an intact monolayer 
formation (Fig. 8). 
Figure 8: HMEC-1 Monolayer. A cobblestone- pattern of cells typical of HMEC-1 cell 
line after three days of growth. Magnification: 200X. 
The integrity of the monolayer was measured using the Bradford Protein Assay. A 
standard curve was first created and later used to calculate the amount of protein 
(albumin) that leaked through the monolayer on each day starting from day 3 of cell 
growth. The data in Figure 9 show the growth trend. Also, the data show that 20,000 cells 
could form an intact monolayer between 5-7 days of growth. 
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Figure 9: Time( in days) for HMEC-1 Monolayer Development. A plot showing an 
intact monolayer formation between 5-7 days of cell proliferation when 20,000 cells were 
seeded in a transwell insert. The inhibition of albumin leakage into the bottom chamber 
was used as an indication of a hnctional and intact monolayer. The data represent means 
of triplicates of three independent experiments. 
Does LPS Affect the Myeloperoxidase (MPO) Assay? 
To ensure that LPS does not negatively impact the experimental results its effect 
on the MPO ELISA assay was tested. To do this, an experiment was done to compare the 
background buffer (control) and LPS in buffer (experiment) on different concentrations 
of myeloperoxidase. A standard curve was developed using standard myeloperoxidase 
solution provided in the commercial kit. The results listed in Table 1 demonstrate that at 
the various concentrations of myeloperoxidase listed, LPS is comparable to the control 
(buffer). Hence, LPS has no negative effect on MPO ELISA assay. The data were means 
of replicated experiment of three in two independent experiments (N=6 +I- S.D.). 
Table 1 : Testing the Effect of LPS on MPO Assay to Rule out Possible Interference 
What is LPS's Effect on HMEC-1 Viability? 
In an effort to determine LPS's effect on HMEC-1, a viability test was performed 
using the MTT-based assay, which was developed by Mosmann (1983) and quantifies the 
mitochondria1 activity of cells as a measure of cell viability[67]. Cells were treated with 
Experimental Conditions 
Buffer only 
100ngIml MPO 
5ngIml MPO 
Onglml MPO 
LPS (lnglml) in Buffer 
100ngIml MPO 
5ngIml MPO 
Onglml MPO 
Mean I'rotein 
Measured (nglml) 
58.5 
13.0 
0 
54.0 
13 .O 
0.12 
Standard Deviation 
+I- 4 
+I- 1.6 
0 
+I- 4.3 
+I- 2 
+I-0.08 
different concentrations of LPS ranging from Ong/ml to lng/ml for one hour (Fig. 10). All 
three LPS concentrations had a stimulatory effect on HMEC-1 as compared with the 
control (P< 0.05). In another experiment by Dr. Tran (data unavailable), cells exposed up 
to 100ng/ml LPS for 4 hours were still viable. Thus, LPS enhances HMEC-I cell line's 
activity and sustains their viability. 
0.25ngf-d 0.5ng'ml 
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Figure 10: Effect of LPS on HMEC-1 viability. HMEC-1 cells exposed to different 
LPS concentrations, 0.25ng/ml, O.Sng/rnl, and lnglml for one hour show a continuous 
increase in viability (PC 0.05). 
PMN Transmigration in the presence of LPS and Protein Synthesis Inhibitors (PSI) 
An investigation of inhibition of PMNs transmigration across the HMEC-1 
monolayer was performed. LPS (lng/ml) was used to stimulate transmigration while PSI 
( 0 . 5 ~  M Puromycin + 0.12 yM Anisomycin) was used to inhibit transmigration. The 
preliminary data (Figure 1 1) showed approximately 60% less transmigration in both the 
positive control (LPS only) and the experimental model compared to the control. 
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Figure 11:  The inhibitory effect of LPS on PMN transmigration. The positive control 
(LPS only) shows an inhibition of PMN transmigration compared with the control 
(P<0.05). The data represent the means +/- 1 standard deviation of duplicates of two 
independent experiments (N= 4). 
LPS Causes PMN to degranulate on Contact 
Following these unexpected observations with LPS's effect on transmigration 
experiment, LPS's direct effect on PMNs was tested to determine the effect should the 
two ever come into contact anytime during the experiment. lnglml LPS was added 
directly to PMNs and then the effect on myeloperoxidase release was determined starting 
from 0 to 30 minutes. The findings in Figure 12 show degranulation of PMNs occurred 
within seconds of "zero time" when exposed to LPS. In another experiment, PMNs were 
exposed to LPS, PSI, and LPS-PSI for 30 minutes. The suspension was centrifuged at 
18000 x g for 15 minutes at 4°C to pellet the PMN. The PMNs were lysed with 
cytobuster and then the MPO ELISA assay was perfomed on the suspension. There was a 
20% loss of myeloperoxidase with LPS compared with the control (Figure 13) 
Interestingly, it appeared the presence of PSI prevented the release of MPO by LPS- 
mediated degranulation. These data (Figures 12 and 13) gave a possible explanation for 
our observations in Fig. 1 1, which indicates a possible residual LPS in the transwell 
inserts could interfere with the transmigration assay. The findings led us to switch from 
using LPS to activate PMN transmigration through endothelial cells to TNFa. 
LPS Causes PMN Degranulation On Contact 
Time (minutes) 
Figure 12: LPS induces neutrophil degranulation on contact when added directly to 
PMNs. Myeloperoxidase activity was measured even at zero minutes and steadily 
increases at 30 minutes. 
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Figure 13: Comparing the direct effect of LPS, PSI, LPS-PSI on PMNs. There was 
loss of myeloperoxidase in LPS treatment compared with the control (Pc0.05). PSI 
prevents PMN degranulation when added alone or with LPS. Experiment was in 
duplicate of two independent experiments. 
Determination of the TNFa Concentration Required for Optimal Transmigration 
Initial efforts were made to determine the appropriate TNFa concentration for the 
PMN transmigration assay by exposing separate endothelial cell preparations to Ong/ml, 
2ngIm1, 5ng/ml, and lOng/ml TNFa respectively for 4 hours. Then a transmigration test o 
was performed on the treated PMN to determine which TNFu concentration would 
produce the maximum transmigration. Comparing the three concentrations used with the 
baseline, lOng/ml of TNFu treatment for four hours (Figure 14) enhanced maximum 
PMN transmigration with P< 0.05. The data were means values of triplicate of two 
separate experiments +I- standard deviation of 9%. 
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Figure 14: The effect different TNFa concentrations on PMN transmigration. TNFa 
( 1  Ong/ml) show significant transmigration compared to the control (Ondml), 2ng/ml, and 
5ng/ml (PC 0.05). 
Determination of PSI'S Effect on PMN Transmigration in the Presence of TNFa 
Having successfully established a workable TNFa concentration for our 
transmigration assay it was necessary to determine if PNIN transmigration would be 
inhibited by the PSI cocktail at that TNFa concentration. Controls, TNFa, PSI and PSI- 
TNFa (experimental) were set up. For the experimental models, the monolayers were 
pre-treated with PSI for one hour and then TNFa was added for an additional four hours 
giving a total time of 5 hours for PSI and 4 hours for TNFa. The results indicate PSI 
wells, with or without T'NFa, show about 80% increase in transmigration compared to the 
negative control (Fig. 15). To rule out a possible effect of a "high" TNFa concentration 
(lOng/ml) counteracting PSI'S ability to inhibit PMlV transmigration, the experiment was 
therefore repeated with a lower TNFa concentration of 5ng/ml. Once again, the data 
(Figure 15b) gave similar results with an even higher (120% more than control) PMN 
transmigration in the experimental wells. Figures 15 represents the mean values of PMN 
transmigration +I- standard deviations. 
PSI'S Inhibition of PMN Transmigration with 10nglml TNF-alpha 
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Figure 15: Inhibition of PMN transmigration by PSI in the presence of lOng/ml 
TNFa. PMNs were inhibited with PSI-TNFa compared with TNFa alone (P> 0.05). PSI 
showed a significant increase in PMN transmigration compared with the control (P< 
0.05). The experiment was in triplicate (n=3) +I- S.D. 
Is PSI treatment for 5 hours too long? 
To answer this question, a time course experiment was performed on the effect of 
PSI'S on HMEC- I for up to 5 hours. Cell viability after exposure to PSI was measured 
using the MTT-based assay, which uses mitochondrial activity as an index of cell 
viability. The result of the experiment illustrated in Figure 16 shows that within the first 
hour of PSI exposure, HMEC-1 increases in metabolic activity up to 40% above the 
control. However, with two hours of PSI exposure HMEC-1 loses 25% metabolic activity 
and then gradually bounces back with 1 10% viability at 4 hours. At 5 hours of PSI 
treatment, the cells lost 20% viability. 
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Figure 16: A time course of PSI'S effect on cell viability. Mitochondria1 activity was 
the measure of cell viability. The first hour shows a significant increase in mitochondrial 
metabolic activity (PC 0.05), while the fifth hour show a loss in viability (PC 0.05). The 
data represent means of triplicate experiments +I- 1 S.D. 
Determination of the Effect of TNFa and PSI on E-selectin expression in HMEC-1 
The ability of TNFa to stimulate E-selectin and PSI'S ability to repress their 
expression in our assay was investigated. Four groups of HMEC-1 cells were treated with 
TNFa and /cr PSI fib; a negzti dt cr ~ t r o l  in the absence of serum. 4fter treatment, cells 
were stained with anti-E-selectin antibody and the samples analyzed by flow cytometry. 
E- selectin was expressed in all groups. Below are illustrations of the results of the 
control cells (34%) and TNFa -treated cells (72%) showing E-selectin expression (Fig. 
17 a & b). The con~plete results obtained are summarized in Figure 17c with 37% of PSI- 
treated cells and 60% of PSI-TNFa treated cells showing E-selectin expression. 
Although, E-selectin is endogenously expressed in all groups, TNFa activation doubles 
the E-selectin expression compared to the control (P< 0.05). Also, PSI-TNFa treated cells 
show 12% decrease in E-selectin expression compared with the expression with TNFa 
activation. The data represent the means +I- 1 S.D. of triplicate samples per treatment of 
three experiments. 
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Figure 17: Analysis of endogenous E-selectin expression in HMEC-1. (a) An 
illustration of Control cells with E-selectin shown in the X -region (b) An illustration of 
TNFa- treated cells with E-selectin shown in the K-region. (c) A graphical presentation 
of the percent levels of E-selectin in the HMEC-1 exposed to different experimental 
conditions. 
Does Serum Induce E-selectin Expression in HMEC-l? 
Of all the conditions exposed to HMEC-1 in the study, serum was the condition 
common to all cells. The next question that needed to be addressed was does serum then 
induce E-selectin in HMEC-l? In order to investigate serum's ability to induce E-selectin 
in HMEC-1 , it was necessary to determine the effect of lack of serum on cell growth. 
Therefore, an investigation to determine the importance of serum to HMEC-I growth was 
performed. One group of cells was cultured in medium with 20% FBS (control), a second 
group of cells was grown in a serum-free medium, and a third group of cells was grown 
in a medium with Insulin-Transferrin-Selenium-A (ITS). The experiment was inspired by 
a similar study with bovine calf chondrocytes (Kisiday et a1 2005). Control cells had a 
robust growth forming a cobblestone-shaped pattern by 96 hours (Figure 18). For cell 
groups cultured in both serum-free and ITS media, cells established growth within 24 
hours but showed a decline till by 96 hours, growth was sparse with increase in dead cells 
in the serum-free category and stunted growth with ITS medium (Figure 18). When 0.2% 
serum was added to the dying cells in ITS medium on day five of growth, cell began to 
show characteristics of healthy growth in as little as 24 hours (Figure 19a & b). 
First 24 hours of Cell Growth 
(a) Control- 20%FBS (b) Serum-free growth medium (c) ITS growth medium 
96 hours of Growth 
(d) Control (e) Serum-free 
Figure 18: Growth pattern of HMEC-1 cultured in different growth media. 
(a) Control cells at 24 hours (b) Serum-free cells at 24 hours (c) ITS cells at 24 hours (d) 
(d) Control cells show compact, cobblestone- shaped cells at 96 hours (e) Serum -free 
cells show a lot of floating (dead) cells at 96 hours (f) ITS cells show sparse and 
malnourished at 96 hours 
Figure 19: HMEC-1 growth response to 0.2% serum after serum starvation. (a) 
Stunted growth after 5 days with serum -free ITS- supplemented medium. (b) HMEC- 1 
return to healthy growth within 24 hours of 0.2% serum addition. 
Analyzing Endogenous E-selectin Expression level with Reduced Serum in Growth 
Medium 
After establishing the importance of serum to HMEC-1 growth, the effect of low 
serum concentrations on E-selectin expression in control cells (no treatment) 
investigated. Since ITS + 0.2% serum showed a positive growth response, HMEC- 1 were 
exposed to different media combinations of ITS plus 0.2%, 1%, and 2% serum 
concentrations and the corresponding level of E-selectin expressed were investigated. A 
FACS analysis of the various serum concentrations indicated the following: cells cultured 
in growth medium with 0.2% serum had 4% of cells expressing E-selectin. Also cells 
grown in medium with 1 % and 2% serum had 7% and 9% respectively of cells 
expressing E-selectin. 
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3. Cells grown in 2% serum 
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Figure 20: Low concentration of Serum induces lower levels of  E-selectin in HMEC- 
l.(a) cells in 0.2% serum (b) cells in 1% serum (c) cells in 2% serum. The E-selectins 
are expressed in the fourth quadrant(J4). 
Does Apoptosis Occur in HMEC-1 during Treatment With or Without Serum? 
Two groups of HMEC- I cells were exposed to TNFa, PSI, PSI-TNFa, and 
no treatment (control). One was provided with serum during treatment and the other 
received treatment in the absence of serum. They were both analyzed by flow 
cytometry for apoptosis. The data show in the presence of serum apoptosis was 
prevented in 50% or more cells. Cells that did not receive serum during treatment 
showed total apoptosis of 80% or more. 
Lack of Serum Induces Apoptosis in HMEC-1 
Negative Control TNFa PSI 
Exposed Conditions 
Figure 21: Lack of serum induces apoptosis in HMEC-1. Measurement of apoptosis in 
HMEC- 1 during TNFa and PSI treatments in the presence of or lack of serum. The 
addition of serum during treatments improved the number of healthy cells available for 
transmigration. 
Determination of PMN Transmigration through HMEC-1 Exposed to Low Serum 
Concentration 
Inhibition of PMN transmigration by PSI was performed with cells exposed to 
ITS + I % .  Other modifications considered were: the one-hour PSI pre-treatment was 
eliminated to prevent cell over-exposure to PSI and to allow enough time for TNFa to 
'stimulate adhesion molecules expression necessary for transmigration. In addition, IL-8 
was replaced with 10% serum not only to serve as chemoattractant, but also to restore 
serum back to HMEC- 1 cells after serum starvation during the treatment period. With 
1 % serum supplement in the growth medium the data show that PMN transmigration was 
inhibited by 16% with PSI compared to the transmigration with TNFa activation (Figure 
22). Due to the low number of replicates (N=2) used in this experiment, the statistics 
could not be adequately performed. The results, however, indicated a trend, which was 
honed by a slight experimental modification. Cells were exposed to 2% serum in growth 
medium instead of 1 %. With this additional modification, PMN transmigration was 
inhibited by 66% in PSI-TNFa cotreated monolayers with P< O.OS(Figure 23). 
Inhibition of PMN Transmigration 
Control TNF-a PSI 
Experimental Condition 
Figure 22: Inhibition of PMN transmigration by PSI 1 .  PSI inhibits PMN 
transmigration compared with activity in TNFa treated monolayer. The data represent 
mean values of N=2 +I- S.D. The statistics could not be done due to the small sample 
size, but data show an interesting trend. 
Inhibition of PMN Transmigration by PSI 
Control :-a PSI PSI-TNF-a 
:perimental Conditions 
n=3 
PSI-TNF I _ -  
Figure 23: Inhibition of PMN transmigration by PSI 2. PSI inhibits PMN 
transmigration in PSI-TNFa compared with TNFa control. PSI alone also 
significantly inhibits PMN transmigration compared with the control (P< 0.05, N= 3 
+I- S.D.). 
HMEC-1 Exposed to 2% Serum Reflects Low E-selectin Expression 
Flow cytometry analysis of the E-selectin associated with 2% serum - 
cultured HMEC- 1 cells exposed to the various treatment conditions, show expressed 
percent E-selectin as follows: Control (22%), TNFa (29%), PSI (14%), and TNFa-PSI 
( 10%). The data represents means of two readings from two experiments (Figure 24 and 
Appendix 7). Figure 25 also compares E-selectin induced by 20% serum with that by 2%. 
E-selectin Induced by 2% Serum 
TNFa PSI TNFa-PSI 
Treatment Condilions 
Figure 24: Analysis of E-selectin induced by 2% serum exposure. Data represents 
means +/-I  S.D. of analyses from two independent experiments 
Comparing E-selectin Induced with Serum Concentration 
Control TNFa PSI 
Treatment Conditions of HMEC-1 
-- 
m20% ~ @ N I T  
.2% Serum 
- 
Figure 25: A comparison of E-selectin levels induced by Serum: 20% versus 2% 
serum. A FACS analysis of cells exposed to 20% serum yields higher E-selectin levels 
than cells exposed to 2% serum (P<0.05). 
Discussion 
Acute respiratory distress syndrome (ARDS), an imminent sequel of severe 
trauma has a mortality rate of up to 40%. However, there is no known study regarding 
prevention of this syndrome. Our current study on the inhibition of neutropl~il 
transmigration sets the stage for a possible future intervention of ARDS. The purpose of 
the project, therefore, was to inhibit neutrophil transmigration by repressing the 
biosynthesis of adhesion molecules, which are indispensable for transmigration, on 
endothelial cells using Protein Synthesis Inhibitors (PSI). The expectation is that in the 
presence of PSI stimulating cytokines such as TNFa or a bacterial peptide like LPS will 
fail to enhance neutrophil transmigration. 
In order to ascertain the efficacy of the assay, an in vitro model, which mimics the 
natural in vivo system of blood vessel and tissue compartment, was developed (Figure 7). 
Specifically, the upper chamber of the model with a coat of monolayer of cells 
represented the lumen and the endothelium of the microvascular capillary. The lower 
chamber, which was made up of a well from a 24-multiwell plate containing a 
chemoattractant, represented the tissue milieu. Human microvascular endothelial cells 
(HMEC-1) produced from human lung tissues were used for the experiments. It was 
established that the model system requires 20,000 HMEC-1 seeded in 6.5 mm diameter 
transwell inserts for 5-7 days to develop sufficiently intact monolayer for the assay 
(Figure 9). Throughout the experiment, no leakage problems were observed with this 
monolayer density. 
Originally the endotoxin, lypopolysaccharide (LPS) was selected as an 
inflammatory stimulus. However, previous reports [68,69] had indicated that LPS 
affects pulmonary endothelium in diverse and complicated manner. Furthermore, LPS' 
effect varies both in vivo and in culture and between species and cellular origin. It was, 
therefore, necessary to rule out any interference that LPS might have in the experiment. 
Thus, LPS' effect on the MPO ELISA assay was investigated by testing various 
concentrations of myeloperoxidase standard solution against LPS. The data showed no 
negative effect of LPS on the MPO assay (Table I), an indication that LPS would not 
interfere with the MPO assay. Next, LPS' effect on HMEC- 1 was tested and the results 
showed that HMEC- 1 was viable with the LPS concentrations of 0.25ng/ml,O.5ng/ml 
and 1 nglml (Figure 10). Furthermore, in a previous study, Dr. Quincy Tran (personal 
communication) recorded HMEC- 1's viability with LPS concentrations of up to 
100ngIml. From these data, it was concluded that LPS does not cause HMEC-1 damage 
or death. An assertion, which Hu et a1 support[70]. 
Equipped with this information, the transmigration of neutrophils through LPS- 
activated monolayer was preformed. In another set up of the same experiment, protein 
synthesis inhibitors (0.5 pM Puromycin and 0.12pM Anisomycin) were used to prevent 
the transmigration. Unexpectedly, the results showed 60% inhibition of PMN 
transmigration even in the LPS (positive) control. This observation was very interesting 
and it supported the fact that LPS might be inhibiting rather than enhancing PMN 
transmigration. To examine this possibility, an investigation into the nature of LPS' effect 
on PMNs was conducted. The myeloperoxidase activity data in Figure 12 suggested that 
within seconds of zero time LPS caused an instant degranulation of PMN following 
contact. In another experiment, the direct effects of LPS and LPS- PSI on PMNs were 
tested. The experiment recorded that as much as 20% loss of the total myeloperoxidase 
content with associated with LPS treatment (Figure 13) while PSI-LPS treated PMNs had 
myeloperoxidase content comparable with the control. Based on the findings of the 
experiment, a reason attributable to the loss of myeloperoxidase in the LPS -treated 
neutrophil is early degranulation of PMN following contact with LPS. Some of the 
myeloperoxidase released may have been lost to the supernatant after a centrifugation. 
Hence, the significantly low PMN transmigration observed in LPS-activated endothelial 
cells (P< 0.05) may have resulted from residual LPS in the monolayer. Khan et. a1 
suggested LPS impaired neutrophil emigration and chemotaxis is due to a p38 MAPK- 
mediated inhibition of neutrophil responses to endogenous chemokines [7 11. 
Following this finding, TNFa was substituted for LPS as an endothelial cell 
stimulant. It was established in the experiment that a 4-hour treatment time of 1 Onglml 
TNFa was necessary to stimulate HMEC-1 to up- regulate the necessary adhesion 
molecules to allow significant PMN transmigration (Figure 14). However, when PSI was 
tested for its ability to block PMN transmigration, an unexpected finding was observed. 
In PSI- and PSI-TNFa -treated monolayers, PMN transmigration was enhanced to 80% 
compared to the control [P< 0.051 in the presence of 10ngIml TNF-a (Figure 15). 
However, a look at PSI control suggested that PSI rather than TNFa might be inducing 
transmigration. 
A viability test (MTT assay) on HMEC-1 with PSI was done to determine the 
time dependent effect of PSI on HMEC-1. With one hour PSI exposure, cell viability was 
up by 40% over the control (P< 0.05), but the numbers dropped by the second hour 75% 
and gradually increased to about 105%(comparable with the control) and plummeted 
again to 80% in the fifth hour. While there is no immediate explanation for the 
fluctuation in cell viability with PSI exposure over the five-hour period, 20% loss in cells 
number after the five hours of PSI treatment was significant to consider reducing the total 
HMEC- 1 exposure time to PSI. Thus, in subsequent transmigration tests PSI exposure 
time was reduced to four hours. 
Since the goal of the project was to target protein biosynthesis, E-selectin, an 
adhesion molecule synthesized de novo [18] became the focus of the research. So an 
investigation was conducted to determine E-selectin expression with TNFa activation of 
endothelial cells and a possible blockade with PSI. Flow cytometry analysis of all 
categories of cells (treated and non-treated) revealed the biggest surprise yet. The data 
revealed E-selectin expression in allcell groups regardless of their treatment status 
(Figure 17 and Appendix 7). Control (untreated) cells alone showed 34% E-selectin 
expression, which was doubled (72%) with 10ngIml TNFa activation. Also, PSI- and 
TNFa-PSI- treated cells indicated 37% and 60% of cells respectively with E-selectin 
(Figure 17c). The two-fold increase in E-selectin expression with TNFa activation 
however, confirms TNFa's ability to up-regulate adhesion molecules on the surface of 
the endothelial cells. 
These unexpected findings of endogenous E-selectin expression initiated an 
investigation of what may have caused it. A quick look at the various experimental 
conditions exposed to HMEC-1 indicated serum as the common denominator to all 
groups of cells. Thus, selecting serum as the focus of investigation to determine the cause 
of the endogenous expression of E-selectin production and it is consistent with other 
investigators reports of serum's ability to induce various proteins in eukaryotic cells [72, 
731. 
The effect of lack of serum on HMEC-1's growth was then studied to determine if 
HMEC-1 could still function well in the absence of serum. Three categories of HMEC-1 
cells were cultured in three separate growth media: 20% FBS- supplemented medium 
(control), Serum-free medium, and Insulin-Transferrin-Selenium-A (ITS) medium. The 
data indicated that after four days of growth, while the control cells were well formed and 
looked healthy, growth was severely impaired in cells supplied with the two other media 
(Figure 18). However, when shrunken cells resulting from ITS diet were supplied with as 
little as 0.2% serum, normal growth resumed and cells began to look healthier within 24 
hours (Figure 19). From these observations, it was obvious that eliminating serum from 
the growth medium interfered with HMEC- 1's ability to function adequately. 
In another experiment to determine how vital serum is to HMEC-1's optimal 
performance, apoptosis was investigated in cells that continue to receive serum during 
the various treatment conditions versus cells that did not receive any serum in the 
treatment period. Figure 2 1 show that regardless of the type of treatment received, 
apoptosis was induced at higher percentages in cells that had no serum during treatment 
period than in cells that continued to receive serum during treatment. Additionally, cells 
that received serum had 50% or more healthy cells for subsequent transmigration. 
Another interesting finding was that cells receiving TNFa without serum registered 93% 
apoptosis. This rather strange observation could imply TNFa may induce apoptosis in 
HMEC-1 in the absence of serum. In general, although, the number of healthy cells was 
improved with serum addition during treatment, 50% of cells lost to both apoptosis quiet 
disturbing and could hurt our goal of greatly inhibiting PMN transmigration. 
Since serum exposure seemed to play a big role in the transmigration assay, it 
became necessary that the appropriate serum concentration required to support HMEC-1 
growth without interfering with the expected results, be determined. To do this, cells 
grown in 11 S medium with different serum concentrations of 0.2%, 1%, or 2%, were 
analyzed for E-selectin expression by flow cytometry technique. The data revealed a 
dose-dependent serum tied to the percentage of E-selectin expressed. Thus, non-treated 
(control) cells exposed to serum concentrations of 0.2%, 1%, and 2% had 4%, 7%, and 
9% respectively of E-selectin expression (Figure 20). These findings proved to a large 
extent that, serum actually induces E-selectin in HMEC-1. Although, 0.2% serum 
exposure induced the least E-selectin in the cells, cells cultured in medium with 1% or 
2% serum were used in the transmigration assay. The choice made was based on a visual 
observation of cell growth, which indicated a longer time (9-10 days) for cells grown in 
0.2% serum to develop a monolayer as opposed to cells grown in either 1 % or 2% serum, 
which required between 5-7 days for the desired monolayer to form. Following this 
observation, the subsequent transmigration assay was tested on HMEC-1 grown in 1% 
serum. In addition, for the next transmigration assay a few modifications were made. The 
modifications included the elimination of one-hour PSI pre-treatment reducing the 
treatment period to a total time of 4 hours; IL-8 was also replaced with 10% serum in the 
bottom well and served as both chemoattractant and restored serum to the monolayer 
after the short period of starvation. With these adjustments, a 16% inhibition of PMNs 
transmigration was observed in TNFa -PSI co-treated monolayer. In addition, PSI- 
treated cells recorded 20% less PMN transmigration compared to the baseline (Figure 
22). 
The current results continue to make serum concentration an important factor to 
closely monitor. A further increase of serum was adapted and HMEC- 1 for the 
subsequent transmigration assay was cultured in 2% serum (a 1 % increase). The increase 
in serum supply to HMEC- 1 surely made a difference: a 66% inhibition of PMN 
transmigration was observed in TNFa-PSI monolayer compared to TNFa activated 
transmigration [P<0.05] Also PSI treated cells show a 24% inhibition compared with 
control [P< 0.051 (Figure 23). This latter data is very exciting and indicates that with 
proper serum adjustment greater PMN inhibition in transmigration with protein synthesis 
inhibitors can be achieved. The results at this point definitely show an inhibitory trend 
and are significant (P<0.05). However, repeated experiments with larger the sample sizes 
will be helpful. It is also recommended that future experiments include serum 
adjustments to obtain the optimal concentration for HMEC- 1 at which higher inhibition 
could be achieved with reduced endogenous E-selectin expression, which interferes with 
the data. When HMEC- 1 exposed to 2% serum was analyzed for E-selectin, the data 
(Figure 24) show E-selectin proportions, which compares favorably with the trend of 
PMN transmigration observed in Figure 23. For example, TNFa-PSI treated cells with 
the least proportion of E-selectin ( 1  0.6%) also has the least PMN transmigration or the 
most inhibition (P<0.05). In comparing E-selectin expressed with concentration of serum 
made available to the growing cells, it was obvious that 20% serum induces much higher 
E-selectin in HMEC-1 than did 2% senlm (Figure 25). This data clearly show that E- 
selectin endogenously expressed by serum in HMEC-l is dose-dependent. 
Conclusion 
From our current experiments the following observations can be concluded: 
1. It takes 5-7days for 20,000 HMEC- 1 seeded in inserts of 6.5mm diameter, and 
3p.m pore- sized polycarbonate membrane to develop a good monolayer intact 
enough for the transmigration experiment. 
3; 
2; 'The Serum conundrum: while the presence of high concentrated serum induces 
endogenous E-selectin, total serum removal induces apoptosis in HMEC-1. The 
data support that at least 2% serum is optimal to satisfy the maintenance 
requirement of HMEC- 1, but yet not over induce E-selectin. 
3. In this experiment it will require 10ngIml TNFa treatment for four hours to allow 
significant PMN transmigration. 
4. A four - hour co-treatment of PSI and TNFa resulted in a greater inhibition of 
PMN transmigration than a one- hour PSI pre-treatment followed by TNFa 
treatment. 
5. Finally, these studies support our hypothesis that Protein Synthesis Inhibitors can 
be used to block neutrophil transmigration during inflammation. 
Recommendation for Future Studies 
1. Additional work is recommended to further define the optimal serum 
concentration needed to ensure HMEC-1 stability and good health for the period 
of the experiment. 
2. The separate dose-response effects of puromycin and anisomycin on PMN 
transmigration will be necessary. 
3. Studies on the reversible effect of these protein synthesis inhibitors is 
recommended to ensure cell functions are not permanently impaired. 
4. We also recommend that since using PMNs from a daily blood source is a point 
of variability, a transfected or stable PMN cell line should be considered in future 
studies. 
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Appendix 1 
A. Growth Media Preparation 
1. 20% Fetal Bovine Serum 
Mix all ingredients under the lamina flow hood and filter with a filter system 
Ingredient 
FBS 
L-Glutamine 
Antibiotic- 
Antimycotic 
EGF 
Hydrocortisone 
MCDB 13 1 
Total Volume 
2. Preparing an Insulin-Transferrin-Selenium -A (ITS) medium, a 
serum- free medium 
Stock Conc. 
- 
200mM 
1 OOX 
100 pglml 
25 mglml 
1 X 
- 
Mix all ingredients under the hood and filter with a filtering system. 
Ingredients 
ITS- 100X (Gibco #5 1300-044) 
Antibiotic-Antimycotic 
(Gibco# 15240-096) 
L-Glutamine-200mM (Gibco # 
25030-081) 
Hydrocortisone 
MCDB 13 l(Gibco # 10372) 
Total Volume 
Volume added 
100 ml 
5 ml 
5 ml 
200 p1 
20 pl 
390 ml 
500 ml 
Working Conc. 
20% 
2 mM 
1 X 
40 nglml 
1 pglml 
1 X 
- 
Stock Cone. 
100 X 
100 X 
200mM 
25 mglml 
1 X 
- 
Volume 
added 
5 ml 
5 ml 
5 ml 
20 pl 
485 ml 
500 ml 
Working 
Conc. 
1 %(1 X) 
1 %(1 X) 
2mM 
1 pglml 
1 X 
3. Preparing 1 % Serum plus Insulin-Transferrin-Selenium -A (ITS) 
medium, 
Mix all ingredients under the hood and filter with a filtering system. 
Ingredients 
ITS-1 00X (Gibco #5 1300-044) 
Antibiotic-Antimycotic 
(Gibco#15240-096) 
L-Glutamine-200mM (Gibco # 
25030-081) 
Fetal Bovine Serum 
Hydrocortisone 
MCDB 13 1 (Gibco # 10372) 
Total Volume 
Stock Conc. 
100 X 
100 X 
200mM 
- 
25 mglml 
1 X 
- 
Volume 
added 
5 ml 
5 ml 
5 ml 
5 ml 
20 p1 
480 nil 
500 ml 
Working 
Conc. 
1 %(1 X )  
1 %(1 X) 
2mM 
1% 
1 pglml 
1 X 
- 
Appendix 2 
Media Formulations 
a. MCDB 13 l(Tab1e was adapted from http://catalog.invitrogen.com) 
MCDB 131 Medium liquid (1X) 
contains no L-glutarnine. 
MCDB 13 1 was orginially developed by Knedler and Ham as a reduced serum-supplemented medium for the culture of human 
microvascular endothelial cells. This formulation has been reported to support clonal growth of humanomental microvascular cells 
when supplemented with 0.7%dialyzed FBS, 10 nglml EGF, and 1 pglml hydrocortisone. 
Catalog Number: .!.0&7_2N!9 
Glycine 75 2.3 0.0307 
L-Arginine hydrochloride 211 63 2 0.300 
L-Asparagine-H2O 1 SO 15 0.1000 
L-Aspartic ac~d 133 13.3 0.1000 
35 0.199 
LHistidine hydrochloride-H20 
L-Isoleucine 
LLeucine 
183 182 0.995 
149 15 0.101 
33 0 200 
L-Proline 11.5 0.1000 
L-Serine 32 0 305 
L-Threonine 119 12 0.101 
B~otln 
Choline chloride 
D-Calcium pantothenate 
Folinic Acid Calcium salt 
i-Inositol 1 80 7 2 0 0400 
122 6.1 0.0500 
206 2 1 0.0102 
Riboflavin 376 0.0038 0.0000101 
Thiamine hydrochlor~de 337 3.4 0 0101 
Ammonium Metavanadate NaV03 121.93 0.0006 0.0000049 
Ammonium Molybdate ((NH4)6Mo70244H20) 1235 
Calcium Chloride (CaC12-2 
Cupric sulfate (CuS04-5H20 
Ferric sulfate (FeS04-7H20) 
%iagnesium Sulfate (MgS04- 
Manganese Sulfate (MnS04-H20) 169 
;Selenious Acid H2Se03 
Sodium Bicarbonate (NaHC03) 
I I* 
Sodium Chloride (NaCI) 
Sodium Meta Silicate Na2Si03 9H20 284 2.8 0.00986 
Sodium Phosphate dibasic (Na2HP04-7H20) 268 
Zinc Sulfate (ZnS04-H20) 288 0.0003 0.0000010 
Aden~ne 135 0 135 0 001000 
D-Glucose (Dextrose) 180 1000 5.56 
b. Insulin-Transferrin-Selenium-A (1 OOX) Supplement Formulation 
(Gibco # 15240-096, Grand Island, NY) 
I Sodium Selenite 0 . 6 f m g / ~  
Component 
Insulin 
Concentration 
1.0 g/L 
I Ethanolamine 0.2 g/L 
Transferrin 
Sodium Pvruvate 
0.55 g/L 
1 1 .O g/L 
Appendix 3 
Flow Cytometer 
Sheath Fluid Drop-Cha rging Signa 
W bration Tramducer 
Flow Chamber 
P m itbeiy Char ged Negabety  Charged 
Deflection Plate Deflection Plate 
Wade 
A. A schematic view of a flow cytometer and sorter with a jet-in-air configuration 
showing one forward light scatter and two fluorescence detectors. 
Samplp Sheath fluid 
n e e  Samtle l e  
H y d r ~ d  ynamic 
focusing 
zone 
Laser 
beam 
A close up of the Flow Chamber 
Adapted from: www.ueb.cas.cz./. . ./Basicgrinciples.htm 
Appendix 4 
Isolation of PMNs Schematic 
Anahrtical Densitv Gradient Separation 
[Picture adapted from: chemistry.anl.gov/. . ./images/dgc-prep I .jifl 
Procedure 
1. Remove Polymorphprep Solution from 4°C prior to blood separation to 
equilibrate to room temperature. 
2. Obtain whole blood from healthy donors drawn and placed in sterile 3 ml 
vacutainers with EDTA as anticoagulant. 
3. Place 5ml of polymorphprep first in a 15 ml Falcon tube and 5 ml of 
anticoagulated whole blood carefully layered over it. Much care was taken not to 
mix the blood with the separation fluid. 
4. Centrifuge the layered samples at 450- 500 x g for 30-35 minutes in a swing-out 
rotor between 18- 22"C.(NB: blood from some individuals may require a higher 
centrifugal force to separate). For the first time with any individual's blood one 
may have to test spin to know the specific g-force required. 
5. At the end of centrifugation, two distinct leukocyte bands will be visible. The top 
band at the medium interface is mononuclear cells and the lower band of 
polymorphonuclear cells. The bottom pellet is composed of erythrocytes. 
Appendix 5 
Myeloperoxidase ELISA Assay 
Materials (InnozymeTM Myeloperoxidase Activity Kit)[Calbiochem, La Jolla, CAI 
1. 1X Sample Buffer+ lml of 20 X Sample Buffer + 19 ml of dH20 
2. 0.3% H202 + 5p1 of 30% H202 + 495p1 cold dH20 
3. TMB Detection Reagent 
4. ELISA Stop Solution 
5. Assay Buffer 
6. 96-well polystyrene plate coated with antibody 
7. 20 X Sample Buffer 
Procedure 
1. Transfer 475p1 of PMN suspension after transmigration and 25p1 of 20 X Sample 
Buffer into a sterile eppendorf tube. Vortex and dispense 100pl to designated 
wells of a 96-well strips placed in a well holder (NB: these come in individual 
strips so the experiments can be tailored to the number of strips needed). 
2. Cover with a plastic plate sealer provided in the kit 
3. Incubate for 60 minutes by gentle shaking 
4. Wash the plate 4 times with 400 pl of 1X Sample Buffer. Following each wash 
discard the contents of the well by inverting with plate over the sink; tap the plate 
on a paper towel to remove residual liquid. 
5. Add freshly prepared TMB working solution (see Table below for the number of 
strips used and the corresponding Working Solution) to each well and incubate at 
37°C for 20-30 minutes. 
6. Add 100 p1 ELISA Solution to each well to stop the color development. 
7. Read the absorbance at 450nm 
Appendix 6 
- 
Reversibilty o f  P S I  Treatment 
X 0 5 X  0 . 5 X  0  5  
C o n c e n t r a t i o n  o f  P S l  
lX PSI = 1M W n  + 0.25UVlPrisuqan 
Appendix 6: A time course of HMEC-1 recovery after exposure to 0.1X, 0.5X, 
and 1X concentrations of PSI (Puromycin + Anisomycin). [by Quincy Tran]. 
Appendix 7 
FACS Analysis of E-Selectin Expression (54 quadrant) in HMEC-1 cultured 
in 2% of Serum 
a. Negative Control - 6.5% b. TNF(Positive Control) - 29% 
FLI  L O G  
Control (no treatment) - 26% 
1 1  , 1 1 1 ,  1 1 1 , 1 1 1 1  ' " 1 "  
I ,  ' 
" " " '  I I 
1  o0 10 1  o2 111' 
FLI LOG 
d. PSI - 14.4% 
" 1  ' " " " 1  I ' " ' 1 ' '  
t o '  I o1 10 
F L I  LOG F L I  LOG 
e. PSI-TNF - 10.6 % 
FL1 LOG 
Appendix 7: Illustrations of FACS data on the proportions of E-selectin induced in 
cells cultured in 2% serum: (a) Negative control for non-specific binding, 6.5%, forms 
the background (b) TNFa, positive control- 29% (c) Control cells with no treatment- 26% 
(d) 14.4% (e) TNFa-PSI - 10.6% 
